Oncology Brothers

Christopher Wallis, MD, PhD, FRCSC

GU Oncology Now

<p>The Oncology Brothers&mdash;Rahul Gosain, MD, Wilmot Cancer Institute at Webster, and Rohit Gosain, MD, UPMC Hillman Cancer Center&mdash;chat with Christopher Wallis, MD, PhD, University of Toronto, on the ASCO research presented in PARP inhibitors for GU cancers, as well as neoadjuvant immunotherapy and enfortumab vedotin for bladder cancer.<p><a href="https://guoncologynow.com/category/asco-2023" target="_blank" rel="noopener">View more ASCO 2023 videos</a>.</p></p>


The Oncology Brothers, Dr. Wallis Give Their Thoughts on PROpel, TALAPRO-2, and EV-103 Cohort K

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

The Oncology Brothers chat with Dr. Wallis on research in PARP inhibitors for GU cancers, as well as neoadjuvant immunotherapy and EV for bladder cancer.

The Oncology Brothers on PROpel, TALAPRO-2, and EV-103 Cohort K

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe